Dr. Antonarakis describes optimal populations for genetic testing in prostate cancer
Emmanuel S. Antonarakis, MD, explains the optimal patient populations who should receive genetic testing in both the localized and metastatic prostate cancer settings. Antonarakis is discussing genetic testing in patients with prostate cancer during the CME program at the 2022 LUGPA Annual Meeting. He is associate director for Translational Research at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
